372 completed, 127 unknown, 72 terminated, 63 recruiting. 723 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 723 | Completed 372, Unknown 127, Terminated 72, Recruiting 63, Not yet recruiting 38, Withdrawn 34, Active not recruiting 14, Enrolling by invitation 3 |
Follow Intestinal Diseases: new trials by email Literature Review of Intestinal Diseases trials Research Report on Intestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam - Ulcerative Colitis | Phase 4 | Not yet recruiting | Bausch Health Americas, Inc. | 100 | 2029-06-01 | 2026-10-06 |
| ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery 5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis | Phase 4 | Not yet recruiting | University Hospital, Linkoeping | 110 | 2027-04-01 | 2026-08-19 |
| Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study Irrigation with PVI, Usual care - Acute, Perforated Appendicitis | Phase 4 | Not yet recruiting | The University of Texas Health Science Center, Houston | 1750 | 2027-03-01 | 2025-02-10 |
| Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis treatment withdrawal - Ulcerative Colitis in Remission | Phase 4 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 224 | 2027-01-01 | 2026-07-22 |
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 50 | 2026-12-01 | 2026-08-24 |
| FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | University Hospital, Clermont-Ferrand | 240 | 2026-12-01 | 2026-10-21 |
| Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose Upadacitinib - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 100 | 2026-11-15 | 2026-10-29 |
| Tucatinib Continuation Study tucatinib - HER2-positive Breast Cancer, Cervical Cancer | Phase 4 | Not yet recruiting | Pfizer | 175 | 2026-11-06 | 2026-08-28 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Vonoprazan High-Dose Dual VS Levofloxacin Concomitant Vonoprazan, Levofloxacin 500mg - Helicobacter Pylori Infection, Peptic Ulcer Disease | Phase 4 | Not yet recruiting | Damascus Hospital | 150 | 2026-11-01 | 2026-06-03 |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-10-15 | 2026-09-24 |
| Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess Amoxicillin + Clavulanate, Ciprofloxacin + Metronidazole - Perianal Abscess, Anal Fistula | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 236 | 2026-10-05 | 2026-09-21 |
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-23 |
| Combination CurQD and Vedolizumab in Ulcerative Colitis CurQD, Placebo, Vedolizumab - Ulcerative Colitis | Phase 4 | Not yet recruiting | Ryan C Ungaro | 160 | 2026-10-01 | 2026-10-05 |
| PPI Dosing Per CYP2C19 Genotype CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose - Gastroesophageal Reflux Disease With Esophagitis | Phase 4 | Not yet recruiting | University of Florida | 200 | 2026-10-01 | 2026-09-28 |
| Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery Intravenous Methylene Blue, Methylene Blue Fluorescence Imaging System - Colorectal Cancer, Colorectal Surgery | Phase 4 | Not yet recruiting | Chinese University of Hong Kong | 20 | 2026-10-01 | 2026-10-06 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® TyboWe® Adalimumab Injection - Crohn's Disease | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2026-09-23 | 2026-09-24 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease Vancomycin (POC), Fidaxomicin - Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection | Phase 4 | Not yet recruiting | Brigham and Women's Hospital | 60 | 2026-09-01 | 2025-11-03 |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
Showing 20 of 723. Sign in to see all of them.
Crohn Disease (150) · Colitis, Ulcerative (127) · Colorectal Neoplasms (106) · Inflammatory Bowel Diseases (80) · Irritable Bowel Syndrome (58) · Colonic Neoplasms (38) · Peptic Ulcer (36) · Appendicitis (31) · Rectal Neoplasms (22) · Hemorrhoids (19) · Pain, Postoperative (18) · Diarrhea (15) · Stomach Ulcer (15) · Stomach Neoplasms (14)
Digestive System Diseases (718) · Gastrointestinal Diseases (717) · Gastroenteritis (351) · Colonic Diseases (333) · Inflammatory Bowel Diseases (188) · Pathological Conditions, Signs and Symptoms (169) · Neoplasms by Site (168) · Digestive System Neoplasms (167) · Neoplasms (167) · Gastrointestinal Neoplasms (165) · Rectal Diseases (165) · Intestinal Neoplasms (157) · Colitis (126) · Pathologic Processes (96)
Infliximab (42) · vedolizumab (32) · Adalimumab (22) · Metronidazole (21) · Amoxicillin (18) · Mesalamine (17) · Esomeprazole (16) · Azathioprine (14) · Capecitabine (14) · Fluorouracil (12) · Omeprazole (12) · Oxaliplatin (12) · Bevacizumab (11) · Bismuth (11) · Bupivacaine (11)
Takeda (15) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (14) · Xijing Hospital of Digestive Diseases (9) · Mayo Clinic (8) · Fudan University (7) · Hoffmann-La Roche (7) · Universitaire Ziekenhuizen KU Leuven (7) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (6) · Medical University of Warsaw (6) · Sixth Affiliated Hospital, Sun Yat-sen University (6) · Alimentiv Inc. (5) · Cedars-Sinai Medical Center (5) · Merck Sharp & Dohme LLC (5) · University of Wisconsin, Madison (5) · Asan Medical Center (4)
United States (177) · China (82) · Canada (45) · France (44) · Italy (41) · Netherlands (34) · Denmark (31) · Spain (30) · United Kingdom (30) · Belgium (26) · South Korea (26) · Germany (22) · Israel (21) · Poland (18) · Taiwan (17)
Arie Levine, MD (5) · Yongquan Shi, Ph. D (4) · Brian G Feagan, MD (3) · Dan Turner, MD, PhD (3) · Michael Camilleri, MD (3) · Ron Shaoul, MD (3) · Vipul Jairath, MD (3) · Ying Huang (3)
PMID 25018650, PMID 40013523, PMID 40357993, PMID 11668104, PMID 23152962, PMID 37526194, PMID 10395629, PMID 10403850, PMID 10536559, PMID 10626860, PMID 10896917, PMID 10950834, PMID 11052511, PMID 11256129, PMID 12041718, PMID 12127688, PMID 12194122, PMID 12219064, PMID 12432298, PMID 12492746, PMID 14570648, PMID 14644354, PMID 14762782, PMID 1499440, PMID 15058524, PMID 15094271, PMID 15168373, PMID 15479678, PMID 15488052, PMID 15555725, PMID 15572881, PMID 15645403, PMID 15793647, PMID 15838899, PMID 15843939, PMID 15901026, PMID 15915027, PMID 15949202, PMID 16116317, PMID 16254521, PMID 16279893, PMID 16393226, PMID 16393228, PMID 16421419, PMID 16500392, PMID 16611269, PMID 16612915, PMID 16678566, PMID 1669678, PMID 16819379
2014 (9), 2025 (8), 2015 (5), 2017 (5), 2009 (4), 2019 (4), 2016 (3), 2018 (2), 2023 (2), 2008 (1), K12TR004908 (1), K23DK124567 (1), K24DK078228 (1), P30CA046934 (1), R01DK059961 (1)